Deciphera Pharmaceuticals Inc Announces Top-Line Results from the INTRIGUE Phase 3 Clinical Study- Conference Call Transcript

Nov 05, 2021 / 12:00PM GMT
Operator

Good morning, everyone, and welcome to the Deciphera Pharmaceuticals conference call to discuss INTRIGUE top line data results. Today's call is being recorded. At this time, I would like to turn the call over to Ms. [Megan Myers] You may begin.

Unidentified Company Representative -

Thank you, operator. Welcome, and thank you for joining us today to discuss the top line results from the INTRIGUE pivotal Phase III study of QINLOCK in patients with gastrointestinal stromal tumors, or GIST, previously treated with imatinib. On the call this morning are Steve Hoerter, President and Chief Executive Officer; Matt Sherman, Chief Medical Officer; and Tucker Kelly, Chief Financial Officer.

Before we begin, I would like to remind you that any statements we make on this call that are not historical facts are forward-looking statements, reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements made on this call involve substantial risks and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot